Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis

Gastroenterology

Volumn 148, Issue 4, 2015, Pages 740-750.e2

  Sandborn, William J ^a   Bosworth, Brian ^b   Zakko, Salam ^c   Gordon, Glenn L ^d   Clemmons, David R ^e   Golden, Pamela L ^f   Rolleri, Robert L ^f   Yu, Jing ^f   Barrett, Andrew C ^f   Bortey, Enoch ^f   Paterson, Craig ^f   Forbes, William P ^f  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c Connecticut Gastroenterology Institute ^*  (United States)

^d Center for Digestive and Liver Diseases Inc   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

Colitis Budesonide; Inflammatory Bowel Disease; Ulcerative; Ulcerative Proctosigmoiditis

Indexed keywords

BUDESONIDE; CORTICOTROPIN; HYDROCORTISONE; GLUCOCORTICOID;

ADRENAL INSUFFICIENCY; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; FOAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; REMISSION; SIDE EFFECT; ULCERATIVE COLITIS; ULCERATIVE PROCTITIS; ULCERATIVE PROCTOSIGMOIDITIS; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES; PROCTOCOLITIS; RECTAL DRUG ADMINISTRATION; SIGMOID; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; ULCER;

ADMINISTRATION, RECTAL; ADMINISTRATION, TOPICAL; ADULT; BUDESONIDE; COLON, SIGMOID; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PROCTITIS; PROCTOCOLITIS; REMISSION INDUCTION; TREATMENT OUTCOME; ULCER;

EID: 84925369214     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.01.037     Document Type: Article

References (34)

1. I. Ordás, L. Eckmann, and M. Talamini Ulcerative colitis Lancet 380 2012 1606 1619
2. S.B. Hanauer, D.H. Present, and D.T. Rubin Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes Gastroenterol Hepatol (N Y) 5 2009 4 16
3. R.G. Farmer, K.A. Easley, and G.B. Rankin Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients Dig Dis Sci 38 1993 1137 1146
4. G.R. Lichtenstein, M.T. Abreu, R. Cohen American Gastroenterological Association American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease Gastroenterology 130 2006 935 939
5. J.D. Lewis, J.M. Gelfand, and A.B. Troxel Immunosuppressant medications and mortality in inflammatory bowel disease Am J Gastroenterol 103 2008 1428 1435
6. A. Kornbluth, D.B. Sachar The Practice Parameters Committee of the American College of Gastroenterology Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee Am J Gastroenterol 105 2010 501 523
7. J.K. Marshall, M. Thabane, and A.H. Steinhart Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis Cochrane Database Syst Rev 1 2010 CD004115
8. B.J. Loew, and C.A. Siegel Foam preparations for the treatment of ulcerative colitis Curr Drug Deliv 9 2012 338 344
9. J. Brown, S. Haines, and I.R. Wilding Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy Aliment Pharmacol Ther 11 1997 685 691
10. S.C. Truelove, and L.J. Witts Cortisone in ulcerative colitis; final report on a therapeutic trial Br Med J 2 1955 1041 1048
11. S.C. Truelove, and M.H. Hambling Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial Br Med J 2 1958 1072 1077
12. S.P. Travis, E.F. Stange, and M. Lémann European evidence-based Consensus on the management of ulcerative colitis: current management J Crohns Colitis 2 2008 24 62
13. R. Brattsand Overview of newer glucocorticosteroid preparations for inflammatory bowel disease Can J Gastroenterol 4 1990 407 414
14. S. Edsbäcker, P. Larsson, and P. Wollmer Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules Eur J Gastroenterol Hepatol 14 2002 1357 1362
15. S. Edsbäcker, B. Bengtsson, and P. Larsson A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules Aliment Pharmacol Ther 17 2003 525 536
16. S.B. Hanauer, M. Robinson, R. Pruitt U.S. Budesonide Enema Study Group Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study Gastroenterology 115 1998 525 532
17. F. Hartmann, J. Stein The BudMesa-Study Group Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis Aliment Pharmacol Ther 32 2010 368 376
18. L. Biancone, P. Gionchetti, and G. Del Vecchio Blanco Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study Dig Liver Dis 39 2007 329 337
19. M. Brunner, H. Vogelsang, and R. Greinwald Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis Aliment Pharmacol Ther 22 2005 463 470
20. S. Bar-Meir, H.H. Fidder, M. Faszczyk The International Budesonide Study Group Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis Dis Colon Rectum 46 2003 929 936
21. V. Gross, S. Bar-Meir, A. Lavy The International Budesonide Foam Study Group Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis Aliment Pharmacol Ther 23 2006 303 312
22. K.W. Schroeder, W.J. Tremaine, and D.M. Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study N Engl J Med 317 1987 1625 1629
23. P.C. O'Brien, and M.A. Shampo Statistical considerations for performing multiple tests in a single experiment. 5. Comparing two therapies with respect to several endpoints Mayo Clin Proc 63 1988 1140 1143
24. J.E. Lennard-Jones, G.W. Cooper, and A.C. Newell Observations on idiopathic proctitis Gut 3 1962 201 206
25. S.S. Rao, N.W. Read, and C. Brown Studies on the mechanism of bowel disturbance in ulcerative colitis Gastroenterology 93 1987 934 940
26. M. Brunner, S. Ziegler, and A.F. Di Stefano Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation Br J Clin Pharmacol 61 2006 31 38
27. ® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study Gastroenterology 143 2012 1218 1226
28. S.P. Travis, S. Danese, and L. Kupcinskas Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study Gut 63 2014 433 441
29. S.B. Hanauer, M. Robinson, and R. Pruitt Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group Gastroenterology 115 1998 525 532
30. J. Desramé, J.M. Sabate, and R. Agher Assessment of hypothalamic-pituitary-adrenal axis function after corticosteroid therapy in inflammatory bowel disease Am J Gastroenterol 97 2002 1785 1791
31. J.K. Marshall, and E.J. Irvine Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis Gut 40 1997 775 781
32. S.G. Matts, B.A. Wharton, J. Kelleher, and G. Walters Adrenal cortical and pituitary function after intrarectal steroid therapy Br Med J 2 1963 24 26
33. A. Hammond, T. Andus, M. Gierend German Budesonide Foam Study Group Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis Hepatogastroenterology 51 2004 1345 1349
34. A. Cortot, D. Maetz, and E. Degoutte Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis Am J Gastroenterol 103 2008 3106 3114